Mibeaz Indications/Uses

Primary Hypercholesterolemia: Ezetimibe administered with HMG-CoA reductase inhibitor (statin) or alone is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), triglycerides (TG), non-high-density lipoprotein cholesterol (non-HDL-C) and to increase high-density lipoprotein cholesterol (HDL-C) in adult and adolescent (10-17 years of age) patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia.
Ezetimibe administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of evaluated total-C, LDL-C, apo B, and non-HDL-C in adult patients with mixed hyperlipidemia.
Prevention of cardiovascular disease: Ezetimibe with a statin, is indicated to reduce the risk of cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, or need for revascularization), in patients with coronary heart disease (CHD).
Prevention of major cardiovascular events in chronic kidney disease: Ezetimibe, administered with simvastatin, is indicated to reduce the risk of major cardiovascular events in patient with chronic kidney disease.
Homozygous familial hypercholesterolemia (HoFH): Ezetimibe, administered with a statin, is indicated for the reduction of elevated total-C and LDL-C levels in adult and adolescent (10 to 17 years of age) patients with HoFH. Patient may also receive adjunctive treatments (e.g. LDL apheresis).
Homozygous familial sitosterolemia (Phytosterolemia): Ezetimibe with diet is indicated for the reduction of elevated serum sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.